Last reviewed · How we verify
nasal dexmedetomidine
Nasal dexmedetomidine, marketed by Zhihong LU, is a drug currently available in the market with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | nasal dexmedetomidine |
|---|---|
| Also known as | saline |
| Sponsor | Zhihong LU |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring (NA)
- General Anesthesia Versus Sedation By Dexmedetomidine and Ketamine With Local Infiltration for Percutaneous Transcatheter Closure of Atrial Septal Defect in Pediatric Patients (NA)
- Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS) (NA)
- Dexmedetomidine Nasal Spray and Pediatric Bronchoscopy (NA)
- Opioid-Free vs Opioid-Based Anesthesia for Nasal Surgeries (PHASE3)
- Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status (PHASE3)
- The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavioral Changes in Children With Autism Spectrum Disorder (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nasal dexmedetomidine CI brief — competitive landscape report
- nasal dexmedetomidine updates RSS · CI watch RSS
- Zhihong LU portfolio CI